Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 15, Issue 4, Pages 453-464Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2015.1014807
Keywords
drug adherence; drug-drug interactions; drug-food interactions; lymphoma; oral chemotherapy; targeted therapy
Categories
Ask authors/readers for more resources
The advent of newer, targeted oral chemotherapy medications such as small molecule kinase inhibitors, ibrutinib and idelalisib, has created additional options for the treatment of lymphoma. The targeted nature of these agents offers many patient-identified advantages over older, intravenously administered chemotherapy regimens such as ease of self-administration and an increased sense of independence. However, newer oral agents also present unique challenges not previously experienced with older therapies that may affect safety, efficacy and patient adherence. In this article, we review oral agents for the treatment of lymphoma, how to evaluate and manage drug-drug and drug-food interactions with concomitant oral medications, and issues with patient adherence as well as methods to determine adherence for oral chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available